AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor

Abstract

The chemokine receptor CX3 CR1 has been implicated as an attractive therapeutic target in several diseases, including atherosclerosis and diabetes. However, there has been a lack of non-peptide CX3 CR1 inhibitors to substantiate these findings. A selective small-molecule inhibitor of CX3 CR1, AZD8797, was recently reported and we present here an in-depth in vitro characterization of that molecule. In a flow adhesion assay, AZD8797 antagonized the natural ligand, fractalkine (CX3 CL1), in both human whole blood (hWB) and in a B-lymphocyte cell line with IC50 values of 300 and 6 nM respectively. AZD8797 also prevented G-protein activation in a [35 S]GTPγS (guanosine 5′ -[γ -thio]triphosphate) accumulation assay. In contrast, dynamic mass redistribution (DMR) experiments revealed a weak Gαi -dependent AZD8797 agonism. Additionally, AZD8797 positively modulated the CX3 CL1 response at sub-micromolar concentrations in a β-arrestin recruitment assay. In equilibrium saturation binding experiments, AZD8797 reduced the maximal binding of 125I-CX3 CL1 without affecting Kd . Kinetic experiments, determining the kon and koff of AZD8797, demonstrated that this was not an artefact of irreversible or insurmountable binding, thus a true non-competitive mechanism. Finally we show that both AZD8797 and GTPγ S increase the rate with which CX3 CL1 dissociates from CX3 CR1 in a similar manner, indicating a connection between AZD8797 and the CX3 CR1-bound G-protein. Collectively, these data show that AZD8797 is a non-competitive allosteric modulator of CX3 CL1, binding CX3 CR1 and effecting G-protein signalling and β-arrestin recruitment in a biased way.